- Home
- EQ
as 11-21-2024 4:00pm EST
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 24.8M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 304.3K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $3.25 | Next Earning Date: | 11-13-2024 |
| Revenue: | $45,914,000 | Revenue Growth: | 7.70% |
| Revenue Growth (this year): | -1.68% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Equillium Inc. (EQ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Keyes Jason A | EQ | Chief Financial Officer | Nov 14 '24 | Sell | $0.70 | 10,000 | $7,000.00 | 47,720 | |
| Zedelmayer Christine | EQ | Sr. Vice President and COO | Oct 28 '24 | Sell | $1.25 | 15,000 | $18,750.00 | 135,246 | |
| Keyes Jason A | EQ | Chief Financial Officer | Sep 26 '24 | Sell | $0.81 | 10,000 | $8,100.00 | 47,720 | |
| Tom Penny | EQ | Principal Accounting Officer | Sep 16 '24 | Sell | $0.85 | 38,806 | $32,985.10 | 10,051 |
Latest Equillium Inc. News
EQ Breaking Stock News: Dive into EQ Ticker-Specific Updates for Smart Investing
Business Wire
9 days ago
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
Business Wire
9 days ago
Equillium to Present at the Stifel Healthcare Conference
Business Wire
10 days ago
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
Zacks
16 days ago
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
MT Newswires
22 days ago
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires
22 days ago
Top Midday Decliners
Zacks
22 days ago
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Business Wire
22 days ago
Equillium Maintains Rights to Itolizumab Following Ono Partnership
Compare EQ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EQ Equillium Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.